DealScape | Healthcare Services M&A: Stabilizing, but Highly Strategic
The healthcare services M&A market in mid-2026 didn't experience a sudden, massive snapback, but the downward slide has officially stopped. As we navigate the second half of the year, conditions remain highly workable—provided your process and positioning are executed correctly.
While the broader market remains disciplined, strategic opportunities are opening up for high-quality platforms and medical service organizations (MSOs). Here are the key trends driving healthcare services transactions right now:
1. Private Equity is Active, but Highly Selective
Private equity sponsors still have significant capital to deploy, but they are filtering opportunities through a much tighter lens.
High-Interest Sectors: Home-based care, behavioral health, dental, and veterinary practices continue to lead sponsor interest. Buyers are actively looking for companies with scalable back-office infrastructure and a clear, demonstrable growth story.
Add-ons vs. Platforms: Buy-and-build strategies are driving the vast majority of current deal volume. Strategic add-ons are moving quickly, while larger platform transactions are reserved for businesses that genuinely stand out from the pack.
2. A Rising Tide of State-Level Regulatory Scrutiny
Regulatory compliance is no longer just a legal checklist item; it is actively dictating deal viability and timelines. State governments have aggressively ramped up enforcement to regulate corporate medicine and MSO structures.
Oregon: The state's landmark law (SB 951) officially went into effect on January 1, 2026, for new medical partnerships. It stands as the strictest law in the country, explicitly banning dual ownership by MSO stakeholders in physician practices and severely restricting an MSO’s final decision-making power over business operations like billing, coding, and clinical staffing. (Note: While a major factor for medical platforms, this specific law currently exempts dental and veterinary structures).
Massachusetts and Pennsylvania: Massachusetts is actively enforcing its expanded oversight laws, requiring strict transaction notices for "significant equity investors" and granting the state AG heavy investigative powers over MSOs. Meanwhile, Pennsylvania continues to expand its review powers over changes in control.
For founders operating under an MSO model—especially those eyeing an exit within the next 12 to 24 months—this is the time to audit your risk exposure. During due diligence, sophisticated buyers are digging deep into clinical autonomy, fee-splitting compliance, and the structural alignment between corporate ownership and clinical operations.
3. The Valuation Gap is Widening
We are seeing a clear bifurcation in market valuations.
Premium, top-decile healthcare assets are still clearing the market at premium multiples. However, average businesses face a much tougher environment. Buyers are pushing back with longer transaction timelines, heavier diligence demands, and intense scrutiny regarding margin sustainability and future growth visibility. In short: what used to be a passable financial and operational story is no longer enough to command top dollar.
The Bottom Line
Strong outcomes and high multiples are entirely achievable for healthcare practices and MSOs that enter the market prepared. Success right now requires a pristine financial story, ironclad regulatory compliance, and a sharp strategic narrative.
In this market environment, meticulous process design and targeted buyer selection matter just as much as your initial valuation target.If you are looking to scale your healthcare platform through acquisition or are evaluating the right time to transition, let's connect for a confidential conversation.